The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma

Andrés J M Ferreri, Giuseppina P. Dognini, Osnat Bairey, Arpad Szomor, Carlos Montalbán, Barbara Horvath, Judit Demeter, Lilj Uziel, Riccardo Soffietti, John F. Seymour, Achille Ambrosetti, Rein Willemze, Maurizio Martelli, Giuseppe Rossi, Anna Candoni, Amalia De Renzo, Claudio Doglioni, Emanuele Zucca, Franco Cavalli, Maurilio Ponzoni

Research output: Article

55 Citations (Scopus)

Abstract

Some case reports and a Japanese series suggest benefit from the use of rituximab in patients with intravascular large B-cell lymphoma (IVL). Rituximab efficacy was evaluated in Western patients with IVL, comparing outcome of 10 patients treated with rituximab + chemotherapy (R-CT) and of 20 patients treated with chemotherapy alone (CT). There were no significant differences in patients' characteristics between the two subgroups. The addition of rituximab was associated with improved complete remission rate (90% vs. 50%; P = 0.04), event-free survival (3-year: 89% vs. 35%; P = 0.003) and overall survival (3-year: 89% vs. 38%; P = 0.01). In conclusion, rituximab may substantially change the dismal prognosis of IVL.

Original languageEnglish
Pages (from-to)253-257
Number of pages5
JournalBritish Journal of Haematology
Volume143
Issue number2
DOIs
Publication statusPublished - okt. 2008

Fingerprint

Anthracyclines
B-Cell Lymphoma
Drug Therapy
Disease-Free Survival
Rituximab
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma. / Ferreri, Andrés J M; Dognini, Giuseppina P.; Bairey, Osnat; Szomor, Arpad; Montalbán, Carlos; Horvath, Barbara; Demeter, Judit; Uziel, Lilj; Soffietti, Riccardo; Seymour, John F.; Ambrosetti, Achille; Willemze, Rein; Martelli, Maurizio; Rossi, Giuseppe; Candoni, Anna; De Renzo, Amalia; Doglioni, Claudio; Zucca, Emanuele; Cavalli, Franco; Ponzoni, Maurilio.

In: British Journal of Haematology, Vol. 143, No. 2, 10.2008, p. 253-257.

Research output: Article

Ferreri, AJM, Dognini, GP, Bairey, O, Szomor, A, Montalbán, C, Horvath, B, Demeter, J, Uziel, L, Soffietti, R, Seymour, JF, Ambrosetti, A, Willemze, R, Martelli, M, Rossi, G, Candoni, A, De Renzo, A, Doglioni, C, Zucca, E, Cavalli, F & Ponzoni, M 2008, 'The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma', British Journal of Haematology, vol. 143, no. 2, pp. 253-257. https://doi.org/10.1111/j.1365-2141.2008.07338.x
Ferreri, Andrés J M ; Dognini, Giuseppina P. ; Bairey, Osnat ; Szomor, Arpad ; Montalbán, Carlos ; Horvath, Barbara ; Demeter, Judit ; Uziel, Lilj ; Soffietti, Riccardo ; Seymour, John F. ; Ambrosetti, Achille ; Willemze, Rein ; Martelli, Maurizio ; Rossi, Giuseppe ; Candoni, Anna ; De Renzo, Amalia ; Doglioni, Claudio ; Zucca, Emanuele ; Cavalli, Franco ; Ponzoni, Maurilio. / The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma. In: British Journal of Haematology. 2008 ; Vol. 143, No. 2. pp. 253-257.
@article{7714315490c840c3b40957e9f75e2bb5,
title = "The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma",
abstract = "Some case reports and a Japanese series suggest benefit from the use of rituximab in patients with intravascular large B-cell lymphoma (IVL). Rituximab efficacy was evaluated in Western patients with IVL, comparing outcome of 10 patients treated with rituximab + chemotherapy (R-CT) and of 20 patients treated with chemotherapy alone (CT). There were no significant differences in patients' characteristics between the two subgroups. The addition of rituximab was associated with improved complete remission rate (90{\%} vs. 50{\%}; P = 0.04), event-free survival (3-year: 89{\%} vs. 35{\%}; P = 0.003) and overall survival (3-year: 89{\%} vs. 38{\%}; P = 0.01). In conclusion, rituximab may substantially change the dismal prognosis of IVL.",
keywords = "Anti-CD20 therapy, Extranodal lymphoma, Immunotherapy, Intravascular large B-cell lymphoma, Rituximab",
author = "Ferreri, {Andr{\'e}s J M} and Dognini, {Giuseppina P.} and Osnat Bairey and Arpad Szomor and Carlos Montalb{\'a}n and Barbara Horvath and Judit Demeter and Lilj Uziel and Riccardo Soffietti and Seymour, {John F.} and Achille Ambrosetti and Rein Willemze and Maurizio Martelli and Giuseppe Rossi and Anna Candoni and {De Renzo}, Amalia and Claudio Doglioni and Emanuele Zucca and Franco Cavalli and Maurilio Ponzoni",
year = "2008",
month = "10",
doi = "10.1111/j.1365-2141.2008.07338.x",
language = "English",
volume = "143",
pages = "253--257",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma

AU - Ferreri, Andrés J M

AU - Dognini, Giuseppina P.

AU - Bairey, Osnat

AU - Szomor, Arpad

AU - Montalbán, Carlos

AU - Horvath, Barbara

AU - Demeter, Judit

AU - Uziel, Lilj

AU - Soffietti, Riccardo

AU - Seymour, John F.

AU - Ambrosetti, Achille

AU - Willemze, Rein

AU - Martelli, Maurizio

AU - Rossi, Giuseppe

AU - Candoni, Anna

AU - De Renzo, Amalia

AU - Doglioni, Claudio

AU - Zucca, Emanuele

AU - Cavalli, Franco

AU - Ponzoni, Maurilio

PY - 2008/10

Y1 - 2008/10

N2 - Some case reports and a Japanese series suggest benefit from the use of rituximab in patients with intravascular large B-cell lymphoma (IVL). Rituximab efficacy was evaluated in Western patients with IVL, comparing outcome of 10 patients treated with rituximab + chemotherapy (R-CT) and of 20 patients treated with chemotherapy alone (CT). There were no significant differences in patients' characteristics between the two subgroups. The addition of rituximab was associated with improved complete remission rate (90% vs. 50%; P = 0.04), event-free survival (3-year: 89% vs. 35%; P = 0.003) and overall survival (3-year: 89% vs. 38%; P = 0.01). In conclusion, rituximab may substantially change the dismal prognosis of IVL.

AB - Some case reports and a Japanese series suggest benefit from the use of rituximab in patients with intravascular large B-cell lymphoma (IVL). Rituximab efficacy was evaluated in Western patients with IVL, comparing outcome of 10 patients treated with rituximab + chemotherapy (R-CT) and of 20 patients treated with chemotherapy alone (CT). There were no significant differences in patients' characteristics between the two subgroups. The addition of rituximab was associated with improved complete remission rate (90% vs. 50%; P = 0.04), event-free survival (3-year: 89% vs. 35%; P = 0.003) and overall survival (3-year: 89% vs. 38%; P = 0.01). In conclusion, rituximab may substantially change the dismal prognosis of IVL.

KW - Anti-CD20 therapy

KW - Extranodal lymphoma

KW - Immunotherapy

KW - Intravascular large B-cell lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=52649165593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649165593&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2008.07338.x

DO - 10.1111/j.1365-2141.2008.07338.x

M3 - Article

VL - 143

SP - 253

EP - 257

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -